An independent pharmacist’s map of ownership, equity interests and financial relationships in retail medicine.
A map simplifies the territory. This one makes the connections easier to examine: who owns which businesses, who pays whom, and where the independent pharmacy sits among them. It cannot capture every contract or local circumstance. Its concern is what concentrated power costs the community pharmacy and the people who depend on it.
A prescription transaction uses several kinds of information. The National Drug Code identifies the product and package. WAC, AWP and NADAC provide different price references. The contract determines which reference applies and how payment is calculated.
NDC
National Drug Code
Reference
Identifier structure
NDC = labeler · product · package
Identifies the price record; it does not calculate a price.
What it identifies
A drug’s labeler, product and package through three code segments. Different packages or labelers can have different NDCs for medicines with the same active ingredient.
Where it comes from
FDA assigns the labeler code. The labeler assigns the product and package codes and submits listing information to FDA. A labeler may be a manufacturer, repackager or relabeler.
How it is used
Pharmacy purchasing, claims and pricing records use the product identifier to match a transaction to the relevant drug and package. The NDC does not itself specify a price, FDA approval or coverage.
Why a package and a claim may show different formats
As of this guide’s research date, FDA uses 10-digit NDCs in several segment formats; reimbursement commonly uses an 11-digit format with leading zeros. FDA’s uniform 12-digit format takes effect March 7, 2033. That FDA rule does not itself change the HIPAA reimbursement format. Use the appropriate conversion and product record; do not treat a formatting difference alone as a different medicine.
WAC is manufacturer-set. A WAC-plus contract uses + instead of −.
Quantity uses the benchmark’s unit: tablet, mL or gram. Discount is a percentage; fee is per fill. Payment examples are totals before other contract limits or adjustments, including MAC and usual-and-customary limits; the patient share is part of that total.
What it measures
The manufacturer’s list price to wholesalers or direct purchasers before discounts and rebates.
Where it comes from
The manufacturer reports the list price. Commercial drug-pricing publishers distribute it.
How it is used
Purchasing and reimbursement agreements can reference WAC and apply a discount or other adjustment. It does not establish the pharmacy’s actual net purchase cost.
Publisher-supplied; no universal formula converts WAC to AWP.
Quantity uses the benchmark’s unit: tablet, mL or gram. Discount is a percentage; fee is per fill. Payment examples are totals before other contract limits or adjustments, including MAC and usual-and-customary limits; the patient share is part of that total.
What it measures
A published list-price benchmark used in contracts. It is not a measured average of what a particular pharmacy paid.
Where it comes from
Commercial pricing publishers maintain AWP records. It is not a CMS invoice survey.
How it is used
An agreement may pay “AWP minus” a percentage. The referenced product, effective date and discount determine the dollar result; other contractual limits may also apply.
Monthly mean = sum of retained unit-cost observations ÷ observation count
Generic monthly update
NADAC = (mean this month + mean last month + mean two months ago) ÷ 3
Example: NADAC-plus payment
Payment = published NADAC per unit × quantity + fee
CMS applies grouping, outlier review and weekly updates. The three-month average applies to generics. Methodology
Quantity uses the benchmark’s unit: tablet, mL or gram. Discount is a percentage; fee is per fill. Payment examples are totals before other contract limits or adjustments, including MAC and usual-and-customary limits; the patient share is part of that total.
What it measures
A national reference derived from surveyed retail community pharmacy invoice prices.
Where it comes from
CMS publishes the survey results through Medicaid. Monthly files incorporate survey findings, with updates between monthly releases.
How it is used
States may use NADAC in approved Medicaid reimbursement methods. It is also a comparison point for acquisition costs. The file’s units and effective date matter; a pharmacy’s actual cost may differ.
Read the quantity and unit before comparing prices.
Illustrative calculation:
Establish the package cost: $40 for 100 tablets.
Calculate the unit cost: $40 ÷ 100 = $0.40 per tablet.
Apply the dispensed quantity: 30 × $0.40 = $12 of inventory.
Compare reimbursement for those 30 tablets with the $12 acquisition cost, then account for dispensing expenses.
Confirm the product, package, quantity, pricing unit and date. Comparing the full $40 package price with payment for only 30 tablets would give the wrong result.
An NDC identifies the product/package record. The prescription’s quantity tells the claim how much was dispensed. The applicable contract and pricing record determine the payment calculation.
Other terms used in the flowchart
Health plan / plan sponsor
The insurer, employer or other organization responsible for the benefit’s financing and design.
PBM — pharmacy benefit manager
A business hired or used to administer prescription benefits, including claims, networks and manufacturer negotiations.
Formulary
The plan’s list of covered medicines, subject to applicable coverage conditions.
Claim / adjudication
The pharmacy’s request for coverage and payment, and the administrator’s evaluation of that request.
Reimbursement
The payment allowed for the pharmacy’s dispensing transaction. Patient cost sharing can be part of the total.
MAC — maximum allowable cost
An ingredient-payment ceiling, commonly used for generics. Its amount need not equal the pharmacy’s purchase invoice.
Dispensing fee
A payment component intended to compensate the work and cost of dispensing, separate from the ingredient amount.
Rebate
A price concession paid under a manufacturer agreement. The recipient and pass-through obligations depend on the program and contract.
Spread pricing
An arrangement in which the PBM retains a difference between the sponsor-side claim charge and pharmacy-side payment, compared on equivalent terms.
Vertical integration
Common ownership of businesses at different levels of the system, such as an insurer, a PBM and a dispensing pharmacy.
Coverage approval, inventory purchasing and reimbursement operate under different rules and on different schedules. A prescription can satisfy one requirement while remaining blocked or financially unsustainable elsewhere.
Clinical & coverage
Clinical need and the treatment covered by the benefit.
Inventory & acquisition
Available stock, purchasing terms and acquisition costs.
Payment & reconciliation
Revenue received, outstanding balances and the cost of providing care.
The numbers organize the explanation; they do not represent a single processing timeline.
Scope: the outpatient pharmacy benefit. “Care plan” here means an insurance / managed-care plan; clinical care planning is covered in the patient–pharmacist connection. Part B drugs, 340B and dual eligibility have separate rules, explained below. This is a map of major relationships, not every possible contract.
Ownership
The company setting a pharmacy’s payment terms can also own its competitor. An independent pharmacy may have to accept that company’s network terms to keep serving its own patients. FTC staff documented concentrated bargaining power, opaque reimbursement and preferential payments to affiliates. Ownership explains the conflict; the contracts and payment records show how it operates. [01][02]
Vertically integrated
SAME CORPORATE FAMILY
These businesses operate as separate legal entities under a common parent. Payments between affiliates are not automatically additional consolidated profit. The relevant questions concern their influence over patient access, reimbursement and competition.
Independent pharmacy
OUTSIDE THAT FAMILY
HEALTH PLANExternal payer
↓ delegates administration
PBMExternal contract & network
↓ sets contracted payment
PHARMACYLocal owner carries the inventory
An independent pharmacy may use a pharmacy services administrative organization (PSAO) to administer network contracts. This arrangement does not give the pharmacy ownership of the insurer or PBM, or guarantee comparable negotiating power.
What the difference means at the counter
Decision or exposure
Integrated corporate family
Independent pharmacy
Network & patient routing
A PBM affiliate can shape network terms and preferred channels, within applicable rules.
Must qualify for the network; a willing patient alone does not ensure covered access.
Information
Businesses span benefit administration and dispensing; use and sharing of data remain regulated.
Usually sees its claim response and contract, not the entire sponsor–PBM–manufacturer settlement.
Revenue opportunities
Insurance, administration and dispensing businesses can contribute to the parent.
The dispensing payment must support the drug purchase and local operation; separate services may earn separate fees.
PBMs describe their role as pooling purchasing power, negotiating discounts and administering benefits. Evaluating those claims requires examining net costs, retained compensation, patient access and pharmacy reimbursement under the actual contract. [09]
Calculations
One 30-tablet fill · illustrative dollars, real payment mechanisms
All inputs cover the same full prescription quantity. Patient payment is included in pharmacy revenue. This model excludes rebates, taxes, audits, usual-and-customary limits and aggregate guarantees. Retained spread is before PBM expenses and is not net profit. It does not establish fraud. NADAC mode changes only the pharmacy-side formula.
MAC and “lesser of” reimbursement clauses
Maximum allowable cost (MAC) is an ingredient reimbursement ceiling, commonly applied to generics. A contract may pay the lesser of an AWP formula, MAC, usual-and-customary cash price, or other limits. The stated AWP rate may therefore be superseded by a lower limit. Identify the clause that determined payment and whether a product was available to purchase at that cost. [03]
Distinguishing rebates, spread and pharmacy margin
A manufacturer rebate is a later price concession to a purchaser or its intermediary. Spread is the difference between what a PBM receives for a claim and what it pays the pharmacy, on comparable terms. Pharmacy margin is pharmacy revenue minus acquisition and operating costs. A contract can pass through rebates yet retain spread, or eliminate spread while charging explicit administrative fees. Medicaid statutory rebates go through government rebate arrangements, rather than automatically being paid to the dispensing pharmacy. [07][14]
Acquisition costs and professional dispensing fees
NADAC averages invoice prices; off-invoice concessions are not necessarily captured, and a particular pharmacy’s available product or buying terms may differ. A benchmark should be paired with a suitable dispensing payment, timely updates and a way to address acquisition-cost mismatches. Medicaid fee-for-service payment uses state-approved methods; it is not one nationwide “NADAC plus” number. [04][05]
DIR and effective-rate adjustments: date and program matter
Since January 1, 2024, Part D pharmacy price concessions must be reflected in the negotiated price at the point of sale. That change does not guarantee the payment covers acquisition and labor. Audit recoveries and claim corrections are different from pharmacy price concessions. Commercial contracts can also contain aggregate generic or brand effective-rate guarantees; read their period, exclusions and reconciliation terms. [06][03]
Pharmacy costs
COMPOSITE TEACHING SCENARIO / NOT A REAL PATIENT
Example: a refill reimbursed at acquisition cost
The pharmacy paid $14 for the medicine. The approved claim provides $14 in total revenue, including patient cost sharing. This covers the purchase but leaves nothing for prescription checking, preparation, counseling or other operating costs.
Resolving the shortfall may require a reimbursement appeal or review of available alternatives. A treatment change may need prescriber involvement. Each additional task takes staff time while the patient still needs the medicine.
What happens when the claim is rejected?
A rejection can concern eligibility, refill timing, formulary status, prior authorization, quantity, safety edits or network restrictions.
Read the response to identify the rejection reason.
Contact the appropriate party or correct the claim details.
Resubmit when resolved and assess the new response.
A clinical prior-authorization appeal challenges coverage; a MAC appeal challenges pharmacy payment. They are different processes, with different evidence and deadlines. An approval to dispense does not establish that the payment is financially sustainable. [15]
Does a pharmacist’s clinical care plan get paid?
Medication reconciliation, adherence support and coordination with prescribers can be part of clinical care. A separately documented clinical service may have its own payer contract or billing pathway. It is not automatically reimbursed because a drug claim was paid. Part D medication therapy management is a distinct program for eligible beneficiaries; eligibility and delivery arrangements matter. [16]
Medicare Part B, dual eligibility and 340B
Part B covers certain drugs under its own benefit and payment rules, commonly using average sales price (ASP); it is not the ordinary Part D retail pathway. People with both Medicare and Medicaid generally receive Part D-covered drugs through Part D, with Medicaid potentially covering some excluded drugs. 340B provides qualifying covered entities discounted acquisition; duplicate 340B discounts and Medicaid rebates are prohibited. A contract pharmacy arrangement is not the same thing as owning the health plan. [17][18][19]
2026: negotiated Medicare prices add another cash-flow path
Maximum fair prices (MFPs) for the first selected drugs took effect January 1, 2026. The Medicare Transaction Facilitator supports manufacturer effectuation, including refund processes. A pharmacy may need to reconcile acquisition, claim payment and manufacturer refunds across different times. MFP applies to selected drugs and eligible transactions; it is not a replacement benchmark for every prescription. [08]
Power, pricing & public money
From the independent pharmacy counter, the problem is concrete: pay for the medicine, do the work, then dispute a payment that may not cover either. The FTC’s 2024 report describes how concentrated PBM power can pressure unaffiliated pharmacies through unfavorable terms and low reimbursement. These are questions about who bears the cost of care, not merely which pricing formula appears on a contract. [01]
LIST-PRICE INCENTIVES · FTC ALLEGATIONS AND SETTLEMENT TERMS
Compensation can be tied to a price that differs from net cost.
WAC-based compensation or rebate guarantees can create incentives to favor a higher list-price product even when another version has a lower list price. The FTC’s insulin case alleged anticompetitive rebating practices. Its 2026 Express Scripts and Caremark announcements describe proposed terms addressing low-WAC discrimination, list-price-linked compensation and transparency. These announcements do not establish that every existing contract had already changed. [12][13]
Check the records
the competing product versions, net cost after concessions, compensation formula, formulary decision and effective contract terms.
DIFFERENT PAYMENT TERMS · DOCUMENTED SPREAD MECHANISM
The sponsor’s charge can exceed the pharmacy’s payment.
The sponsor and pharmacy may be subject to different contractual formulas. A favorable-looking AWP discount on one side does not reveal the amount paid on the other. Retaining that difference creates spread revenue; it is not automatically net profit or evidence of illegality. CMS has identified the need to account for spread appropriately in Medicaid managed care. [07]
Check the records
sponsor charge, pharmacy reimbursement, patient contribution and separately charged fees for the same claim. The payment calculator shows this mechanism using invented numbers.
AFFILIATED DISPENSING · FTC STAFF FINDING
FTC staff found higher payments to affiliated pharmacies.
FTC staff found higher reimbursement to the Big Three PBMs’ affiliated pharmacies on nearly every specialty generic drug examined in its 2017–2022 study. This is evidence from a defined sample, not an assumption about every prescription or every current contract. [02]
Ownership implications
the parent has an interest in the dispensing business as well as benefit administration. Investigating that conflict requires comparing payments and access conditions across affiliated and unaffiliated pharmacies.
In June 2021, Mississippi officials announced a $55.5 million settlement with Centene resolving Medicaid overpayment allegations involving its pharmacy-benefit operations. Centene denied liability and described the agreements as no-fault settlements. The recovery is documented; it is not a criminal conviction. [22][23]
The question for taxpayers and pharmacies: what was billed, what reached the pharmacy, and what stayed with the intermediary?
PUBLIC FUNDS / CAREMARK · FALSE CLAIMS ACT SETTLEMENT
Government-payment disputes have included alleged false claims.
In September 2014, Caremark agreed to pay $6 million to resolve federal allegations that it under-reimbursed Medicaid for prescriptions that should have been paid by Caremark-administered private plans. DOJ alleged that its claims system improperly deducted copayments or deductibles. DOJ explicitly reported no determination of liability. [24]
The alleged mechanism was shifting costs to Medicaid; this case does not establish below-cost payment to a particular pharmacy.
ACQUISITION BENCHMARKS · INTERPRETATION LIMIT
NADAC can reveal a markup without measuring net profit.
NADAC provides an invoice-based comparison point. Reimbursement substantially above NADAC warrants examination, but the difference does not deduct all operating costs. Conversely, NADAC-based reimbursement can still leave a pharmacy short if its actual acquisition cost is higher or its dispensing payment is inadequate. These are limitations of how the benchmark is applied; they do not establish that the survey itself is corrupted. [04][05]
Check the records
the invoice, benchmark date, units, dispensing fee and any subsequent adjustments.
Different NDCs require a product-level comparison.
An NDC is an identifier, not a source of profit by itself. Comparing claims requires accounting for the product, strength, dosage form, package and quantity. Different product records may carry different acquisition costs or pricing benchmarks. A payment difference requires investigation before it can be attributed to manipulation. [20][03]
Check the records
whether compared records refer to the same product and quantity, which price record was applied, and whether an affordable product was available to the pharmacy.
>$7.3B
Dispensing revenue above estimated acquisition cost. FTC staff’s estimate for the Big Three PBMs’ affiliated pharmacies on studied specialty generics, 2017–2022. NADAC was the acquisition-cost proxy. This is not a net-profit figure; operating costs are not deducted. [02]
Our position: a community pharmacy should not be treated as expendable infrastructure. Someone still has to stock the medicine, answer the phone and counsel the patient. A pricing system that leaves that work unfunded deserves scrutiny, and indifference to the consequences deserves criticism. The cases above establish specific findings and allegations; they are not interchangeable proof that every low payment is fraud.
Documented finding: an agency’s analysis, with its dates and limits. Mechanism: how a contract or payment can work. Illustration: invented numbers used to make the arithmetic visible. None of these establishes wrongdoing in an individual claim.
This guide takes the independent pharmacy’s side: viable local care, transparent payment and accountability for public money. It calls out concentrated market power without treating “monopoly,” an allegation of fraud and a proven violation as interchangeable. State law, benefit type and contract dates still matter.
Effective dates and implementation
FTC settlement announcements for Express Scripts (February 2026) and Caremark (July 2026) describe changes to standard offerings, transparency and cost-based pharmacy compensation. The announcements describe proposed consent terms; implementation dates, final orders and the plan’s chosen offering must be checked before applying them to a claim. The FTC docket reviewed on October 1, 2026 lists proposed settlement documents; this guide does not represent either announcement as proof that every contract has changed. [25][12][13]
